QTX125 TFA 是一种有效且高度选择性的 HDAC6 抑制剂。与其他 HDAC 相比，QTX125 对 HDAC6 具有出色的选择性。QTX125 TFA 具有抗肿瘤作用。
货号:ajcx36250
CAS:N/A
分子式:C25H20F3N3O7
分子量：531.44
溶解度:DMSO : 125 mg/mL (235.21 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects[1].

QTX125 (25-500 nM; 24-48 hours) TFA treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP[1]. In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 TFA (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin[1].QTX125 TFA has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL)[1].

QTX125 TFA (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice[1].

[1]. Montserrat PÉrez-Salvia, et al. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica. 2018 Nov;103(11):e537-e540.